---
title: "Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis"
id: "journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic"
canonical_url: "https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "Journal of the American Heart Association"
source_url: "https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.047301?ai=sg&mi=3&af=R"
published_at: "2026-06-15T12:17:14.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** Journal of the American Heart Association
- **Source URL:** [Original Journal Publication](https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.047301?ai=sg&mi=3&af=R)
- **Published At:** 2026-06-15T12:17:14.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Journal of the American Heart Association, Volume 15, Issue 12 , June 16, 2026. BackgroundThe optimal antithrombotic regimen for peripheral artery disease, balancing thromboembolic and bleeding risks, remains uncertain. This study aimed to compare the efficacy and safety of antithrombotic regimens in patients with peripheral artery disease.MethodsWe reviewed randomized controlled trials evaluating antithrombotic therapies for peripheral artery disease, including aspirin, P2Y12 inhibitors, cilostazol, and rivaroxaban. The primary outcome was major adverse cardiac events, defined as a composite of cardiovascular death, myocardial infarction, and stroke. The secondary outcomes included major adverse limb events, defined as a composite of acute limb ischemia, revascularization, and amputation. The safety outcome was major bleeding, primarily assessed using the Thrombolysis in Myocardial Infarction criteria. We performed a network meta‐analysis to compare antithrombotic regimens.ResultsSeventeen randomized controlled trials involving 44 532 participants were included. Compared with aspirin monotherapy, the following were associated with lower risks of major adverse cardiac events: clopidogrel, 75 mg/d, plus cilostazol, 200 mg/d (hazard ratio [HR], 0.37 [95% CI, 0.20–0.72]), clopidogrel, 75 mg/d, monotherapy (HR, 0.80 [95% CI, 0.67–0.96]), aspirin plus low‐dose rivaroxaban, 2.5 mg twice daily (HR, 0.81 [95% CI, 0.72–0.92]), and aspirin plus ticagrelor, 60 to 90 mg twice daily (HR, 0.81 [95% CI, 0.69–0.96]). Aspirin plus rivaroxaban or ticagrelor showed a lower risk of major adverse limb events compared with aspirin alone. Rivaroxaban monotherapy, 5 mg twice daily, and aspirin plus rivaroxaban or clopidogrel were associated with a higher risk of major bleeding.ConclusionsClopidogrel plus cilostazol or clopidogrel monotherapy might be a balanced strategy in patients with peripheral artery disease.
## Clinical Analysis & Structured Key Points
Journal of the American Heart Association, Volume 15, Issue 12 , June 16, 2026. BackgroundThe optimal antithrombotic regimen for peripheral artery disease, balancing thromboembolic and bleeding risks, remains uncertain. This study aimed to compare the efficacy and safety of antithrombotic regimens in patients with peripheral artery disease.MethodsWe reviewed randomized controlled trials evaluating antithrombotic therapies for peripheral artery disease, including aspirin, P2Y12 inhibitors, cilostazol, and rivaroxaban. The primary outcome was major adverse cardiac events, defined as a composite of cardiovascular death, myocardial infarction, and stroke. The secondary outcomes included major adverse limb events, defined as a composite of acute limb ischemia, revascularization, and amputation. The safety outcome was major bleeding, primarily assessed using the Thrombolysis in Myocardial Infarction criteria. We performed a network meta‐analysis to compare antithrombotic regimens.ResultsSeventeen randomized controlled trials involving 44 532 participants were included. Compared with aspirin monotherapy, the following were associated with lower risks of major adverse cardiac events: clopidogrel, 75 mg/d, plus cilostazol, 200 mg/d (hazard ratio [HR], 0.37 [95% CI, 0.20–0.72]), clopidogrel, 75 mg/d, monotherapy (HR, 0.80 [95% CI, 0.67–0.96]), aspirin plus low‐dose rivaroxaban, 2.5 mg twice daily (HR, 0.81 [95% CI, 0.72–0.92]), and aspirin plus ticagrelor, 60 to 90 mg twice daily (HR, 0.81 [95% CI, 0.69–0.96]). Aspirin plus rivaroxaban or ticagrelor showed a lower risk of major adverse limb events compared with aspirin alone. Rivaroxaban monotherapy, 5 mg twice daily, and aspirin plus rivaroxaban or clopidogrel were associated with a higher risk of major bleeding.ConclusionsClopidogrel plus cilostazol or clopidogrel monotherapy might be a balanced strategy in patients with peripheral artery disease.
## Related Clinical Research

- [NOAC monotherapy vs NOAC+clopidogrel by age in AF patients with drug-eluting stents](https://medichelpline.com/clinical-feed/pubmed-42546025.md) (DOI: 10.1093/ageing/afag224)
- [Bayesian Network Meta-Analysis of P2Y12 Inhibitors After ACS: Efficacy, Bleeding, and Uncertainty](https://medichelpline.com/clinical-feed/medrxiv-2-what-additional-insights-does-a-bayesian-network-meta-analysis-provide.md)
- [Sex Differences in Acute Coronary Syndrome Presentation and Management in Brazilian EMS](https://medichelpline.com/clinical-feed/medrxiv-2-sex-based-differences-in-clinical-presentation-management-and-outcomes-of-acute.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Droplet ADP Secretion Assay (DASA): single-platelet digital detection of primed, active and hyper-](https://medichelpline.com/clinical-feed/biorxiv-13-droplet-microfluidics-reports-digital-and-tuneable-single-platelet-adp.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.